Evidence map›Paper›PMID 42646473›Full record

ArticleMarine drugs2026

Marine-Derived Fungal Metabolite MHO7 Promotes Breast Cancer Apoptosis as a Hippo Pathway Regulator by Modulating the YAP-TEAD Axis.

Xue Ren, Linfei Wang, Yuxuan Huang, Bei Shu, Kerui Hou, Mengyao Chen, Yao Xiao, Jiahong Liang, Hao Yan, Shuaishuai Ding and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Marine drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xue RenDepartment of Radiation and Medical Oncology (Gynecological Cancers), Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430072, China.
Linfei WangDepartment of Radiation and Medical Oncology (Gynecological Cancers), Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430072, China.
Yuxuan HuangDepartment of Radiation and Medical Oncology (Gynecological Cancers), Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430072, China.
Bei ShuDepartment of Radiation and Medical Oncology (Gynecological Cancers), Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430072, China.
Kerui HouDepartment of Radiation and Medical Oncology (Gynecological Cancers), Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430072, China.
Mengyao ChenDepartment of Radiation and Medical Oncology (Gynecological Cancers), Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430072, China.
Yao XiaoDepartment of Radiation and Medical Oncology (Gynecological Cancers), Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430072, China.
Jiahong LiangDepartment of Radiation and Medical Oncology (Gynecological Cancers), Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430072, China.
Hao YanDepartment of Radiation and Medical Oncology (Gynecological Cancers), Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430072, China.
Shuaishuai DingDepartment of Radiation and Medical Oncology (Gynecological Cancers), Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430072, China.
Hui QiuDepartment of Radiation and Medical Oncology (Gynecological Cancers), Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430072, China.ORCID 0000-0002-2923-1019
Jin LuDepartment of Radiation and Medical Oncology (Gynecological Cancers), Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430072, China.
Kui HongDepartment of Radiation and Medical Oncology (Gynecological Cancers), Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430072, China.ORCID 0000-0002-0686-0947
Xin LiuDepartment of Radiation and Medical Oncology (Gynecological Cancers), Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430072, China.

Funding

National Natural Science Foundation of China 81201088National Natural Science Foundation of China 81472550National Natural Science Foundation of China 82073760National Natural Science Foundation of China 82151217National Natural Science Foundation of China 82373787
6 · The paper itself

Abstract

Breast cancer, especially triple-negative breast cancer (TNBC) and endocrine-resistant disease, remains difficult to treat because of limited effective targeted therapies. In this study, we evaluated the antitumor activity and potential mechanism of MHO7, a marine-derived ophiobolin metabolite, in ER-positive ZR-75-30 cells, tamoxifen-resistant LCC2 cells, and TNBC MDA-MB-231 models. MHO7 dose-dependently reduced cell viability, wound closure, and clonogenic growth in ZR-75-30 and LCC2 cells, with IC

Indexed as

Antineoplastic AgentsApoptosisBreast NeoplasmsTriple Negative Breast NeoplasmsAnimalsAquatic OrganismsCell Line, TumorCell ProliferationCell SurvivalFemaleHippo Signaling PathwayHumansMDA-MB-231 CellsMiceMice, NudeMolecular Docking SimulationAntineoplastic AgentsProtein Serine-Threonine KinasesReactive Oxygen SpeciesTranscription FactorsYAP1 protein, humanYAP-Signaling Proteinsanticancer therapybreast cancerHippo signaling pathwayMHO7TEAD

Identifiers

PMID42646473
PMCPMC13514928

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.